MR CLEAN Registry: “Time is Brain” is a Far More Accurate than “Time is Heart”

Time to endovascular treatment after ischemic stroke is strongly associated to functional outcomes.

Protection Systems Reduce Stroke and Mortality in Carotid Artery StentingThis association could be even stronger than previously suggested in more select populations of controlled studies.

 

These findings emphasize that functional outcomes after endovascular treatment could be improved significantly by reducing onset to treatment times.

 

Randomized studies in select acute ischemic stroke patients show that for every hour delay to endovascular treatment functional independence will diminish by 3.4%.


Read also: Endovascular Therapy in Stroke: Much Evidence and Few Trained Operators.


These results might not be generalizable given strict inclusion exclusion criteria, which is why this study looks at the association between time to endovascular treatment and clinical improvement in the daily practice.

 

The MR CLEAN registry (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in The Netherlands) is an ongoing observational prospective of patients from all endovascular treatment centers in the Netherlands.

 

The study looked at time, onset to treatment and onset to successful reperfusion.


Read also: Cost-Effectiveness of Endovascular and Surgical Repair of Complex Aneurysms.


1488 patients with acute ischemic stroke undergoing endovascular treatment were analyzed. Increased time to start endovascular treatment was associated with worse functional outcomes (OR: 0.83 per hour) and 2.2% mortality increase.

 

For every lost hour, chances of functional Independence dropped by 5.3% (modified Rankin scale).

 

Conclusion

Time between endovascular therapy and symptom onset in the daily practice is strongly associated to functional studies, much stronger association than in acute myocardial infarction and primary PCI.

 

Título original: Time to Endovascular Treatment and Outcome in Acute Ischemic Stroke MR CLEAN Registry Results.

Referencia: Maxim J.H.L. Mulder et al. Circulation. 2018;138:232–240.

 

2018-10-23-232-abierto-stroke


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

IVUS-Guided vs. Angiography-Guided Drug-Coated Balloon Angioplasty in the Treatment of Femoropopliteal Lesions

Angiography has traditionally been the primary imaging technique for endovascular therapy guidance in patients with peripheral artery disease. However, as it only provides two-dimensional...

New Carotid PCI All-in-One System

Carotid stenting is equivalent to carotid endarterectomy in terms of major adverse events (death, AMI, and stroke). However, it entails higher risk of minor...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...